Recent news on Frovatriptan

Migraines inextricably linked with menstruation  -  Apr 20, 2007
Hindustan Times,Another research led by Stephen D. Silberstein of Thomas Jefferson University in Philadelphia, studied the use of frovatriptan as it has a long therapeutic

Vernalis plc Announces Pricing and Reimbursement for Frova® in France  -  Apr 2, 2007
Oxfordshire Bioscience Network (press release),Frova® (frovatriptan succinate tablets) is a selective 5-HT 1B/1D receptor agonist approved as an acute oral treatment for migraine headache and its

Endo and Vernalis Plc Announce Three-Month Extension of PDUFA Date ...  -  Apr 2, 2007
Oxfordshire Bioscience Network (press release),Application (sNDA) for Frova® (frovatriptan succinate) 2.5 mg tablets for the expanded indication of short-term prevention of menstrual migraine (MM).

Some facts about migraines  -  Feb 7, 2007
Pittsburgh Post Gazette,Other 5-HT agonists are almotriptan (Axert), naratriptan (Amerge), rizatriptan (Maxalt), zolmitriptan (Zomig), frovatriptan (Frova) and eletriptan (Relpax).

Triptan-Experienced Migraine Patients Find Improved Management ...  Oct 11, 2006
...migraines and have used medications in the triptan class experience better effectiveness and tolerability when they switch to frovatriptan (Frova), according ... -DG News Vernalis Plc: Interim Results for the Six Months Ended 30 June ...  Sep 11, 2006
Parkinson's disease drug, Apokyn(R) (apomorphine hydrochloride injection), as well as co-promoting its migraine drug, Frova(R) (frovatriptan succinate) 2.5 mg ... -PR Newswire

Vernalis Plc Announces FDA Acceptance For Filing Of Frova(R) For ...  Sep 21, 2006
...that the US Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) for Frova(R) (frovatriptan succinate) 2.5 ... -Medical News Today

Vernalis plc: Interim Results for the six months ended 30 June ...  Sep 13, 2006
...s Parkinson’s disease drug, Apokyn® (apomorphine hydrochloride injection), as well as co-promoting its migraine drug, Frova® (frovatriptan succinate) 2.5 ... -Oxfordshire Bioscience Network

Prevention Strategies Reviewed for Women With Migraines  Sep 6, 2006
Miniprophylaxis for menstrual migraine may involve use of naproxen sodium, magnesium, ergotamine tartrate plus caffeine, frovatriptan, naritriptan, or ... -Medscape (subscription)

Vernalis plc and Endo Pharmaceuticals Holdings Inc. Announce North ...  Aug 7, 2006
Endo�), today announced an agreement for Vernalis to license exclusive North American sales and marketing rights to Frova™ (frovatriptan succinate, 2.5mg ... -Biotechnology Investment Today

Systematic approach needed in managing chronic headaches  Aug 1, 2006
The triptans, such as sumatriptan nasal spray, zolmitriptan nasal spray and oral frovatriptan, although not yet sanctioned by the Food and Drug Administration ... -AAP News (subscription)

FDA Warns on Mixing Antidepressants with Migraine Drugs  Jul 20, 2006
Triptans were Amerge (naratriptan), Axert (almotriptan), Frova (frovatriptan), Imitrex (sumatriptan) Maxalt and Maxalt-MLT (rizatriptan), Relpax (eletriptan ... -Psychiatric Times

Endo Pharmaceuticals and Vernalis plc Announce the Filing of the ...  Jul 19, 2006
...that Endo has submitted to the US Food and Drug Administration (FDA) a supplemental New Drug Application (sNDA) for Frova® (frovatriptan succinate) 2.5 mg ... -Yahoo! News

Vernalis Submits New Drug Application For Frova >VNLS  Jul 20, 2006
...that Endo has submitted to the US Food and Drug Administration (FDA) a supplemental New Drug Application (sNDA) for Frova (frovatriptan succinate) 2.5 mg ... -Therapeutics Daily (subscription)



Vernalis plc to Ring the NASDAQ Closing Bell on May 18, 2006  16 May 2006
...trading on NASDAQ in July 1992, is celebrating the positive outcome of the Company's second Phase III efficacy study of Frova(R) (frovatriptan succinate) 2.5 ... - PR Newswire

Vernalis/Endo: gain in menstrual migraine  May 8, 2006
In the study, patients were randomized to receive either placebo or Frova (frovatriptan) for six days in each of three menstrual cycles. ... - Pharmaceutical Business Review

Frova(R) Meets Primary Endpoint In Second Phase III Study For ...  May 10, 2006
...(Nasdaq: ENDP) today announced top-line data from the second Phase III efficacy study of Frova(R) (frovatriptan succinate) 2.5 mg tablets for the short-term ... - Medical News Today

Vernalis Gets Top-Line Data From Frova Phase III Study  May 8, 2006
Monday announced top-line data from the second Phase III efficacy study of Frova (frovatriptan succinate) 2.5 mg tablets for the short-term (six-days per month ... - Therapeutics Daily (subscription)

Antisoma appoints Dr Gary Acton as Chief Medical Officer  Apr 23, 2006
He was responsible for development of the Company's entire portfolio, including the US and European approvals of frovatriptan, a drug now marketed in all major ... - Market Wire

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional